About NicOx

Profile
Pipeline

Products
Naproxcinod
NCX 6560
Full portfolio
Maximizing portfolio
Co-development
Research alliances
Technology
People
Board of Directors
Management Team
Contacts
Careers
Investor & media
Press releases
Investor relations

Fact file
Financials
Corporate governance


Conferences
Home
Directions to NicOx
Site en français


NicOx press releases (2007-2008)
Archives (from 1996 up to date):

 Select a year                  and / or Keyword..    GO

Title
Date
NicOx announces blood pressure analysis from 301 phase 3 study for naproxcinod at EULAR
13/06/2008
NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study
28/05/2008
NicOx announces departure of Damian Marron for CEO position
27/05/2008
NicOx reports first quarter 2008 financial results
14/05/2008
NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc.
13/05/2008
NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
06/05/2008
NicOx signs agreement for the commercial manufacture of naproxcinod drug substance
19/03/2008
NicOx initiates two large ABPM studies for naproxcinod in hypertensive patients with osteoarthritis
03/03/2008
Financial results for full year 2007: NicOx significantly advances clinical programs
03/03/2008
NicOx signs extension of ophthalmology agreement with Pfizer
08/01/2008
NicOx announces Pfizer initiates phase 2 clinical development for PF-03187207 in Japan
03/01/2008
NicOx completes enrollment in second pivotal phase 3 study for naproxcinod and provides development update
14/12/2007
NicOx announces TOPIGEN initiates phase 2 proof of concept study in COPD for TPI 1020
20/11/2007
NicOx’ naproxcinod phase 3 results presented at American College of Rheumatology
12/11/2007
NicOx’ naproxcinod ABPM data presented at American Heart Association
07/11/2007
NicOx reports results for the first nine months of 2007
29/10/2007
NicOx opens US headquarters in New Jersey
15/10/2007
NicOx and Ferrer present promising clinical and preclinical results in dermatology
02/10/2007
NicOx reports TOPIGEN to advance TPI-1020 into phase 2 for COPD following promising clinical results
11/09/2007
First half 2007 financial results: NicOx strengthens balance sheet and advances naproxcinod
30/07/2007
NicOx receives €5 million milestone from Merck & Co., Inc. as drug candidate enters clinic
16/07/2007
NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization
02/07/2007
NicOx initiates third pivotal naproxcinod phase 3 study
29/06/2007
NicOx provides an update on NCX 4016
18/06/2007
NicOx provides an update on the phase 2a study for NCX 1000 conducted with Axcan
11/05/2007
NicOx reports first quarter 2007 financial results
11/05/2007
NicOx recruits Sanjiv Sharma as Vice President Commercial Affairs in the United States
30/04/2007
NicOx initiates second phase 3 study to confirm naproxcinod’s efficacy and improved blood pressure profile
03/04/2007
NicOx announces that Pfizer has disclosed further details of glaucoma trial for PF-03187207
29/03/2007
Clinical development initiated on lead compound in NicOx’ glaucoma collaboration with Pfizer
28/03/2007
NicOx’ 2006 financial results reflect a successful year of strong achievements and value creation
01/03/2007
NicOx announces the success of its €130 million rights issue
14/02/2007
NicOx presents promising pre-clinical results on an NO-donating latanoprost derivative from its glaucoma collaboration with Pfizer
12/02/2007
NicOx announces the terms of its rights issue to advance naproxcinod and broader pipeline
29/01/2007
NicOx launches a €130 million rights issue to advance naproxcinod and broader pipeline
22/01/2007
NicOx receives €5 million milestone payment from Merck & Co. for antihypertensive collaboration
18/01/2007
Click here to be added to our mailing list
  Printable version
Archives (from 1996 up to date)  GO
For more information :  
NicOx:
Karl Hanks, Director of investor relations and Corporate Communications
Tel. +33 (0)4 97 24 53 42 / hanks@nicox.com

Investors in the United States - Burns McClellan :
Lisa Burns
/ lburns@burnsmc.com
Juliane Snowden / jsnowden@burnsmc.com / Tél +1 212 213 0006

Media in the United States - FD:
Jonathan Birt,
Tel +1 212 850 56 34 / jbirt@fd-us.com

Media in Europe - Citigate Dewe:
Sylvie Berrebi,
Tel +44 (0)207 282 2949 • sylvie.berrebi@cititgatedr.co.uk
David Dible, david.dible@citigatedr.co.uk